Jul. 16 at 5:19 PM
$RNXT - A compelling biotech play
Biotech trades thrive on pivotal trial results. Take recent movers like
$INAB or
$TCRT, both surged following positive data from Phase II/III trials.
For example:
$INAB spiked over 150% on favorable gene therapy news
$TCRT jumped 80%+ post interim CAR-T trial updates
Now we look at RNXT, heading into late July with a Phase III trial data being released, targeting locally advanced pancreatic cancer:
- Estimated 400M+ U.S. market
- Orphan Drug exclusivity for runway protection
- Intra-arterial delivery method that's pioneering the standard of care
TA: Flagging on the chart, watching for a breakout that could push toward analyst targets in the
$7–11 range.
Communicated Disclaimer
https://chartingdaily.com/RNXT-stock
